A Roadmap for Immune Effector Cell Therapy in the Community Oncology Setting

Saturday, October 17, 2026

1:30 PM - 2:30 PM EST

Room: B308/309

Program Chair(s)

Scott A. Koepsell, M.D., Ph.D.

Professor and Vice Chair of Clinical Operations
University of Nebraska Medical Center
Omaha, Nebraska

Speaker(s)

BW

Brian While, MLS (ASCP) BB

Medical Laboratory Scientist
Nebraska Medicine
Omaha, Nebraska
Jensyn Cone Sullivan, MD

Clinical Assistant Professor; Director of the Cellular Therapies Laboratory
University of Michigan
Ann Arbor, Michigan

Proposed Session Description: The transition of Chimeric Antigen Receptor (CAR) T-cell therapy from academic or large centers to community practice represents a pivotal shift in oncology. The infrastructure required to deliver CAR T-cell therapies safely outside of the academic/large center setting is formidable. This session provides a deep dive into the logistical, regulatory, and accreditation blueprints necessary to bridge the gap between academic and community access from the collection and laboratory standpoint.

Learning Objectives:

• Understand the logistical challenges of delivering immune effector cell therapies in the community oncology setting.
• Discuss the regulatory and accreditation barriers to providing immune effector cell therapies in the community setting.
• Discuss the impact of limiting access to immune effector cell therapies to large centers or academic centers.
• Explain strategies to navigate the anticipated challenges for new therapy centers